Suppr超能文献

Comparison of autologous serum eye drops with conventional therapy in a randomised controlled crossover trial for ocular surface disease.

作者信息

Noble B A, Loh R S K, MacLennan S, Pesudovs K, Reynolds A, Bridges L R, Burr J, Stewart O, Quereshi S

机构信息

Department of Ophthalmology, Clarendon Wing, The General Infirmary at Leeds, Belmont Grove, Leeds LS2 9NS, UK.

出版信息

Br J Ophthalmol. 2004 May;88(5):647-52. doi: 10.1136/bjo.2003.026211.

Abstract

AIMS

To evaluate the efficacy of 50% autologous serum drops against conventional treatment in ocular surface disorders refractory to normal treatments in a prospective randomised crossover trial.

METHOD

Patients fulfilling ophthalmological and haematological entry criteria were randomised to either 3 months of autologous serum 50% followed by 3 months of their conventional treatment, or 3 months of conventional treatment, followed by 3 months of autologous serum. Clinical assessments, including Schirmer's test, rose Bengal, and fluorescein staining, were carried out on entry and at monthly intervals. Impression cytology was performed at entry, 3 and 6 months. Grading was carried out on degrees of squamous metaplasia and goblet cell density. Subjective comfort was recorded daily using the "faces" scale. These categorical scores were converted to linear measurement using Rasch analysis. Statistical analysis was carried out using Wilcoxon's signed rank test and ANOVA.

RESULTS

16 patients were recruited with 31 eyes studied. The ocular surface diseases chiefly included Sjögren's syndrome (n = 6) and keratoconjunctivitis sicca (n = 5). Impression cytology available in 25 of 31 eyes showed significant improvement on serum treatment, p<0.02. Rasch weighted faces scores were statistically significantly better with serum, p<0.01.

CONCLUSION

The results of this randomised study provide further evidence of the beneficial effects of autologous serum in severe ocular surface disorders. For most of these patients, autologous serum was superior to conventional treatment for improving ocular surface health and subjective comfort.

摘要

相似文献

2
Autologous serum eye drops for dry eye.
Cochrane Database Syst Rev. 2017 Feb 28;2(2):CD009327. doi: 10.1002/14651858.CD009327.pub3.
3
Association between systemic activity ındex and dry eye severity in patients with primary Sjögren syndrome.
Arq Bras Oftalmol. 2019 Jan-Feb;82(1):45-50. doi: 10.5935/0004-2749.20190005. Epub 2018 Nov 1.
5
The efficacy of autologous serum eye drops for severe dry eye syndrome: a randomized double-blind crossover study.
Graefes Arch Clin Exp Ophthalmol. 2014 Apr;252(4):619-26. doi: 10.1007/s00417-014-2599-1. Epub 2014 Feb 25.
6
Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies.
Br J Ophthalmol. 2001 Oct;85(10):1188-97. doi: 10.1136/bjo.85.10.1188.
8
Autologous serum eye drops for dry eye.
Cochrane Database Syst Rev. 2013 Aug 27;8(8):CD009327. doi: 10.1002/14651858.CD009327.pub2.
9
Autologous serum eye drops diluted with 0.5% methylcellulose and 0.9% saline solution: a clinical comparative study.
Arq Bras Oftalmol. 2023 Apr 17;87(5):e20220064. doi: 10.5935/0004-2749.2022-0064. eCollection 2023.

引用本文的文献

1
Evaluating the efficacy of stem cells in treating severe dry eye disease.
World J Stem Cells. 2025 Apr 26;17(4):101891. doi: 10.4252/wjsc.v17.i4.101891.
2
Biological topicals in ocular surface disorders.
Indian J Ophthalmol. 2025 Apr 1;73(4):496-507. doi: 10.4103/IJO.IJO_482_25. Epub 2025 Mar 27.
5
Autologous blood in the management of ocular surface disorders.
World J Exp Med. 2024 Dec 20;14(4):96412. doi: 10.5493/wjem.v14.i4.96412.
6
Recent United States Developments in the Pharmacological Treatment of Dry Eye Disease.
Drugs. 2024 May;84(5):549-563. doi: 10.1007/s40265-024-02031-6. Epub 2024 Apr 23.
7
New advances in medical management of dry eye: optimizing treatment strategies for enhanced relief.
Int Ophthalmol. 2024 Feb 9;44(1):49. doi: 10.1007/s10792-024-02978-1.
9
Allogeneic Serum Eye Drops: A Randomized Clinical Trial to Evaluate the Clinical Effectiveness of Two Drop Sizes.
Ophthalmol Ther. 2023 Dec;12(6):3347-3359. doi: 10.1007/s40123-023-00827-5. Epub 2023 Oct 16.
10
Patient-reported outcomes of serum eye drops manufactured from Australian blood donations and packaged using Meise vials.
Front Med (Lausanne). 2023 Sep 5;10:1252688. doi: 10.3389/fmed.2023.1252688. eCollection 2023.

本文引用的文献

1
The Activities of Daily Vision Scale for cataract surgery outcomes: re-evaluating validity with Rasch analysis.
Invest Ophthalmol Vis Sci. 2003 Jul;44(7):2892-9. doi: 10.1167/iovs.02-1075.
2
3
Construction of measures from many-facet data.
J Appl Meas. 2002;3(4):486-512.
4
Measuring low-vision rehabilitation outcomes with the NEI VFQ-25.
Invest Ophthalmol Vis Sci. 2002 Sep;43(9):2859-68.
5
Controlled study of the use of autologous serum in dry eye patients.
Cornea. 2001 Nov;20(8):802-6. doi: 10.1097/00003226-200111000-00005.
6
Autologous serum eyedrops for dry eyes and epithelial defects: clinical and in vitro toxicity studies.
Br J Ophthalmol. 2001 Oct;85(10):1188-97. doi: 10.1136/bjo.85.10.1188.
8
Serum application for the treatment of ocular surface disorders.
Int Ophthalmol Clin. 2000 Fall;40(4):113-22. doi: 10.1097/00004397-200010000-00009.
9
Treatment of persistent corneal epithelial defect by autologous serum application.
Ophthalmology. 1999 Oct;106(10):1984-9. doi: 10.1016/S0161-6420(99)90412-8.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验